M A E M Wagenmakers
Overview
Explore the profile of M A E M Wagenmakers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruijn N, Wagenmakers M, van Hoek M, Apers J, van der Eerden M, Ozcan B
J Cyst Fibros
. 2023 Jan;
22(3):577-579.
PMID: 36693768
Cystic fibrosis (CF) is incurable and chronic, causing severe multisystemic damage and long-term complications. The most prominent extrapulmonary long-term complication is CF-related diabetes, which is the most reported form of...
2.
Ismailova G, Mackenbach M, van den Hout J, van der Ploeg A, Brusse E, Wagenmakers M
Orphanet J Rare Dis
. 2022 Mar;
17(1):102.
PMID: 35246221
Introduction: Patients with Glycogen Storage Disease type II (GSDII), an inheritable metabolic myopathy also known as Pompe disease, are considered to be at risk for severe COVID-19 due to a...
3.
Wensink D, Langendonk J, Overbey J, Balwani M, Van Broekhoven E, Wagenmakers M, et al.
Genet Med
. 2021 May;
23(9):1616-1623.
PMID: 33941881
Purpose: Patients with erythropoietic protoporphyria (EPP), a severe painful photodermatosis, experience prodromal sensations when exposed to sunlight, which are the "warning signals" to exit the sun, as prolonged exposure causes...
4.
van Kooten H, Roelen C, Brusse E, van der Beek N, Michels M, van der Ploeg A, et al.
Neuromuscul Disord
. 2021 Jan;
31(2):79-90.
PMID: 33386209
Pompe disease is a rare inherited metabolic and neuromuscular disorder, presenting as a spectrum, with the classic infantile form on one end and the more slowly progressive non-classic form on...
5.
Neeleman R, Wensink D, Wagenmakers M, Mijnhout G, Friesema E, Langendonk J
Neth J Med
. 2020 Jul;
78(4):149-160.
PMID: 32641543
Porphyrias are rare metabolic disorders. Lack of awareness and knowledge about the clinical features of porphyrias results in diagnostic and therapeutic delays for many patients. Delays in diagnosing and treating...
6.
Wolters T, Roerink S, Sterenborg R, Wagenmakers M, Husson O, Smit J, et al.
Eur J Endocrinol
. 2020 Jan;
182(3):319-331.
PMID: 31958318
Objective: Acromegaly has a negative influence on health-related quality of life (HRQoL). Previous studies provide limited information on the course of HRQoL during treatment. This study aims to assess the...
7.
Hoevenaren I, Wagenmakers M, Roerink S, Netea-Maier R, Ulrich D, Maal T
Eur J Plast Surg
. 2016 Dec;
39(6):429-434.
PMID: 27932856
Background: Acral overgrowth is a highly common clinical sign in patients with active acromegaly. To what extent this overgrowth persists after long-term remission of acromegaly is largely unknown. Using the...
8.
Wagenmakers M, Roerink S, Schreuder T, Plantinga T, Holewijn S, Thijssen D, et al.
J Clin Endocrinol Metab
. 2016 Aug;
101(11):4142-4150.
PMID: 27552540
Context: In active Cushing's syndrome (CS), patients suffer from endothelial dysfunction and premature atherosclerosis. However, it is uncertain to what extent vascular health recovers after long-term remission. This is highly...
9.
Roerink S, Wagenmakers M, Smit J, van Rossum E, Netea-Maier R, Plantinga T, et al.
Endocrine
. 2016 Feb;
53(1):63-70.
PMID: 26873309
Context: Glucocorticoid receptor (GR) polymorphisms modulate glucocorticoid (GC) sensitivity and are associated with altered metabolic profiles. Objective: To evaluate the presence of GR polymorphisms (BclI (rs41423247), N363S (rs56149945), ER22/23EK (rs6189/rs6190),...
10.
Roerink S, Wagenmakers M, Wessels J, Sterenborg R, Smit J, Hermus A, et al.
Pituitary
. 2014 Jun;
18(3):366-75.
PMID: 24965695
Context: Acromegaly is associated with impaired quality of life (QoL) and causes anatomical disproportions, which may contribute to the decreased QoL after successful treatment. The Derriford appearance scale 59 (DAS59)...